AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

PrEP

Webinar: PrEP Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities

HIV Prevention Trails Network 073

Please join the HIV Prevention Trials Network (HPTN) launch of a Pre-Exposure Prophylaxis (PrEP) study for Black men who have sex with men (BMSM). The new study, HPTN 073, is a demonstration project designed to see if BMSM are willing to use Truvada® for PrEP. Date: Wed, Aug 14, 2013 Time: 2:00 PM EDT Duration: 1 hour 30 minutes…

Implementing HIV Prevention Methods on the Local Level: Mario Perez Discusses Use of PrEP in Los Angeles County

Mario Perez

As outlined in the National HIV/AIDS Strategy, one of the key steps to successfully reducing the number of new HIV infections in the U.S. is expanding targeted HIV prevention efforts using a combination of effective, evidence-based approaches. Recently, we had the opportunity to speak with Mario Pérez, Director of the Division of HIV and STD…

CDC Recommends PrEP for Injection Drug Users

Jonathan Mermin

The Center for Disease Control and Prevention (CDC) today published in the weekly Morbidity and Mortality Weekly Report interim guidance for the use of Preexposure Prophylaxis (PrEP) for the prevention of HIV infection among Injecting Drug Users (IDUs). Results from a randomized controlled trial in Bangkok, Thailand, of a daily oral dose of 300 mg…

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

CDC Logo

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…

Conversations from CROI 2013: CDC’s Dr. Jonathan Mermin

Mermin Croi 2013

During the 2013 Conference on Retroviruses and Opportunistic Infections  (CROI) in Atlanta earlier this month, I had the opportunity to sit down with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. We discussed some of the important research findings being shared at the conference and their implications for our efforts to respond effectively…

Daily-use HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

blog.aids.gov

According to findings of a major HIV prevention trial presented Monday, March 4, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), study participants who received daily oral pre-exposure prophylaxis (PrEP) did not experience any protection against HIV compared to those in the placebo arm, likely because very few were taking the study…

FDA approves first drug for reducing the risk of sexually acquired HIV infection

blog.aids.gov

Today (July 16, 2012), the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for…

FDA Advisory Committees to Examine a Number of HIV Issues in May

FDA

The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…